PHC Holdings Corporation (2GY.F)
| Previous close | 6.75 |
| Open | 6.45 |
| Bid | 6.45 x N/A |
| Ask | 6.75 x N/A |
| Day's range | 6.45 - 6.50 |
| 52-week range | 6.35 - 10.60 |
| Volume | |
| Avg. volume | 11 |
| Market cap | 819.208M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.84 |
| Earnings date | 10 Aug 2024 - 14 Aug 2024 |
| Forward dividend & yield | 0.25 (3.73%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
PR NewswireCorePlus Announces the Deployment of Artificial Intelligence Algorithm for 100% QC of Pap Tests
CorePlus www.corepluspr.com, a precision pathology organization, announced today that it is the first laboratory in the world to operationalize the Techcyte AI algorithm and quality control workflow for cytology-based cervical cancer screening. After more than two years of clinical collaboration with Techcyte, we have achieved the level of precision and accuracy necessary to deploy this tool for use with our patients to provide 100% quality control of all Pap tests, which goes well beyond the re
Business WireEpredia and NovaScan Announce Intent to Enter U.S. Distribution Agreement for MarginScan™ Device for Non-Melanoma Skin Cancer Detection
PORTSMOUTH, N.H., May 03, 2024--Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avanti
Business WireEversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J., April 30, 2024--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes and Ascensia Diabetes Care, a global diabetes care company, announced that Eversense® has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA).
